Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 181 Breast Neoplasms 154 Prostatic Neoplasms 144 Lung Neoplasms 139 Glioblastoma 119 Head and Neck Neoplasms 115 Squamous Cell Carcinoma of Head and Neck 110 Rectal Neoplasms 107 Lymphoma 101 Esophageal Neoplasms 100 Pancreatic Neoplasms 76 Esophageal Squamous Cell Carcinoma 71 Leukemia 70 Neoplasms 67 Brain Neoplasms 67 Lymphoma, Follicular 63 Precursor Cell Lymphoblastic Leukemia-Lymphoma 62 Lymphoma, Non-Hodgkin 62 Lymphoma, Large B-Cell, Diffuse 58 Hodgkin Disease 56 Uterine Cervical Neoplasms 53 Central Nervous System Neoplasms 53 Leukemia, Lymphocytic, Chronic, B-Cell 52 Gliosarcoma 51 Sarcoma 50 Colorectal Neoplasms 50 Neoplasm Metastasis 45 Lymphoma, Large-Cell, Immunoblastic 45 Glioma 44 Burkitt Lymphoma 43

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle-Invasive Bladder Carcinoma × Radiotherapy × Clear all

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡